PharmaEssentia Corporation

Ionis licensed global rights to Phase II polycythemia vera (PV) candidate sapablursen to Ono Pharmaceutical on 11 March. The deal provides near-term and longer-term revenue for a drug candidate the an

Takeda Pharmaceutical envisions a potentially significant market in polycythemia vera (PV) for rusfertide, which it is developing together with Protagonist Therapeutics, after reporting positive Phase

UPDATE – PharmaEssentia has corrected the press release issued 6 January about the Phase III results for Besremi in essential thrombocytopenia to note the incidence of two treatment-related serious ad

The analytical tools encompassed by the concept of real-world evidence are growing increasingly valuable for enhancing early-stage drug development, an area receiving less attention than pivotal trial